A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma
- Sponsor:
- k36 Therapeutics
- Sponsor Study ID:
- K36-MMSET-001
- CTO #:
- 104359
- NCT Number:
- NCT05651932
- Phase:
- I
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Multiple Myeloma
- Study Objectives:
- Determine a recommended Phase 2 dose (Rp2D) and schedule of KTX-1001 and/or the maximum tolerated dose (MTD) and schedule of KTX-1001.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Dominick, Anthony, at dominica@musc.edu
- Study Coordinator, Schaefer, Matthew, at schaefma@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina